P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)

Detalles Bibliográficos
Autores principales: Specht, HM, Pelzel, J, Hautmann, H, Huber, RM, Schossow, B, Molls, M, Multhoff, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072115/
http://dx.doi.org/10.1186/2051-1426-2-S2-P41
_version_ 1782322907461976064
author Specht, HM
Pelzel, J
Hautmann, H
Huber, RM
Schossow, B
Molls, M
Multhoff, G
author_facet Specht, HM
Pelzel, J
Hautmann, H
Huber, RM
Schossow, B
Molls, M
Multhoff, G
author_sort Specht, HM
collection PubMed
description
format Online
Article
Text
id pubmed-4072115
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40721152014-06-27 P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70) Specht, HM Pelzel, J Hautmann, H Huber, RM Schossow, B Molls, M Multhoff, G J Immunother Cancer Poster Presentation BioMed Central 2014-03-12 /pmc/articles/PMC4072115/ http://dx.doi.org/10.1186/2051-1426-2-S2-P41 Text en Copyright © 2014 Specht et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Poster Presentation
Specht, HM
Pelzel, J
Hautmann, H
Huber, RM
Schossow, B
Molls, M
Multhoff, G
P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)
title P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)
title_full P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)
title_fullStr P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)
title_full_unstemmed P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)
title_short P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)
title_sort p67. targeted natural killer (nk) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (nsclc) after radiochemotherapy (rct) – clinical application of nk cells activated by heat shock protein 70 (hsp70)
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072115/
http://dx.doi.org/10.1186/2051-1426-2-S2-P41
work_keys_str_mv AT spechthm p67targetednaturalkillernkcellbasedadoptiveimmunotherapyforthetreatmentofpatientswithnonsmallcelllungcancernsclcafterradiochemotherapyrctclinicalapplicationofnkcellsactivatedbyheatshockprotein70hsp70
AT pelzelj p67targetednaturalkillernkcellbasedadoptiveimmunotherapyforthetreatmentofpatientswithnonsmallcelllungcancernsclcafterradiochemotherapyrctclinicalapplicationofnkcellsactivatedbyheatshockprotein70hsp70
AT hautmannh p67targetednaturalkillernkcellbasedadoptiveimmunotherapyforthetreatmentofpatientswithnonsmallcelllungcancernsclcafterradiochemotherapyrctclinicalapplicationofnkcellsactivatedbyheatshockprotein70hsp70
AT huberrm p67targetednaturalkillernkcellbasedadoptiveimmunotherapyforthetreatmentofpatientswithnonsmallcelllungcancernsclcafterradiochemotherapyrctclinicalapplicationofnkcellsactivatedbyheatshockprotein70hsp70
AT schossowb p67targetednaturalkillernkcellbasedadoptiveimmunotherapyforthetreatmentofpatientswithnonsmallcelllungcancernsclcafterradiochemotherapyrctclinicalapplicationofnkcellsactivatedbyheatshockprotein70hsp70
AT mollsm p67targetednaturalkillernkcellbasedadoptiveimmunotherapyforthetreatmentofpatientswithnonsmallcelllungcancernsclcafterradiochemotherapyrctclinicalapplicationofnkcellsactivatedbyheatshockprotein70hsp70
AT multhoffg p67targetednaturalkillernkcellbasedadoptiveimmunotherapyforthetreatmentofpatientswithnonsmallcelllungcancernsclcafterradiochemotherapyrctclinicalapplicationofnkcellsactivatedbyheatshockprotein70hsp70

Ejemplares similares